Eisai Co., Ltd.｜A human health care company

Certificate of Appreciation from National Department of Health of Papua New Guinea

Eisai's Support towards COVID-19
Eisai's Statement of Commitment for Carbon Neutrality by 2040

Medium- to long-term goals to achieve carbon neutrality
Video Library

Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines
Lymphatic Filariasis Elimination Activities in Kenya

Support for MDA and Provision of Water Tanks

News Release
Latest News
Information

November 19, 2021

EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2021 FOR EIGHTH TIME
November 18, 2021

EISAI RECEIVES THE “MOST LIKED!” IR AWARD AT THE 2021 IR AWARD
November 17, 2021

Update on Regulatory Review of Aducanumab in the European Union
November 12, 2021

New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
November 12, 2021

EISAI PRESENTS NEW ANALYSIS OF LECANEMAB CLINICAL EFFICACY RESULTS FROM PHASE 2B STUDY AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
Consistency of Efficacy Assessments Evaluated Across Various Statistical Methods

November 12, 2021

IR "CTAD：Assessment of the Clinical Effects of Lecanemab, the Correlation of Plasma Aβ 42/40 Ratio with Changes in Brain Amyloid PET SUVr, and Safety from the Core and OLE of the Phase 2 POC Study, in Subjects with Early AD"
November 2, 2021

IR “Second Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2022 [Material, Webcast]”
November 1, 2021

IR “Second Quarter Financial Report for the Fiscal Year Ending March 31, 2022”
September 22, 2021

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY
September 22, 2021

IR “Value Creation Report 2021”

November 24, 2021

Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease
September 22, 2021

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY
April 19, 2021

Eisai formulates the action plan “Diversity & Inclusion 2021”
December 10, 2020

Notice of Emergence of Employees Infected with the Novel Coronavirus at the Bogor Plant in Indonesia
December 3, 2020

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY

Eisai at a Glance

Eisai Group Worldwide

About Eisai

About Eisai TOP

Our pursuit of human health care (hhc)

Eisai's hhc Philosophy

Eisai's hhc Philosophy TOP

Investors

Sustainability

Making our medicines available to those who need them

28 countries 2.02 billion tablets

Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of August 2021)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

Sustainability TOP